R3655
Rubitecan
powder, ≥98% (HPLC)
别名:
9-nitrocamptothecin
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H15N3O6
化学文摘社编号:
分子量:
393.35
UNSPSC Code:
12352204
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
Rubitecan,
SMILES string
CC[C@@]1(O)C(=O)OCC2=C1C=C3N(Cc4cc5c(cccc5nc34)[N+]([O-])=O)C2=O
InChI
1S/C20H15N3O6/c1-2-20(26)13-7-16-17-10(8-22(16)18(24)12(13)9-29-19(20)25)6-11-14(21-17)4-3-5-15(11)23(27)28/h3-7,26H,2,8-9H2,1H3/t20-/m0/s1
InChI key
VHXNKPBCCMUMSW-FQEVSTJZSA-N
biological source
synthetic (organic)
assay
≥98% (HPLC)
form
powder
mp
182-186 °C
solubility
DMSO: 1 mg/mL
storage temp.
room temp
Quality Level
Biochem/physiol Actions
Topoisomerase I inhibitor. Rubitecan induces protein- linked DNA single strand breaks, blocking DNA and RNA synthesis in dividing cells. This mode of action makes rubitecan a potential chemotherapeutic agent, and it has been used with some success against refractory pancreatic cancer.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
J Chen et al.
Drug development and industrial pharmacy, 32(6), 719-726 (2006-08-04)
9-Nitrocamptothecin (9-NC), a newly developed camptothecin derivative, had poor solubility in any pharmaceutically acceptable solvents. One way of improving the solubility is to formulate the drug into liposomes. However, 9-NC has low affinity to lipid membranes resulting in a very
Simin Dadashzadeh et al.
Anti-cancer drugs, 19(8), 805-811 (2008-08-12)
The objective of this study was to evaluate the cytotoxicity and pharmacokinetics of total and lactone forms of 9-nitrocamptothecin (9-NC), an effective antineoplastic drug, after intravenous injection of drug incorporated into poly (DL-lactic-glycolic acid) nanoparticles (NPs). Drug-loaded NPs (9-NC.NP) were
Venita Gresham Watson et al.
PloS one, 6(5), e17561-e17561 (2011-05-17)
To date, the Centre d'Etude Polymorphism Humain (CEPH) cell line model has only been used as a pharmacogenomic tool to evaluate which genes are responsible for the disparity in response to a single drug. The purpose of this study was
William C Zamboni et al.
Cancer chemotherapy and pharmacology, 62(3), 417-426 (2007-10-25)
We evaluated the antitumor activity of two different schedules of docetaxel and 9-nitrocamptothecin (9NC) in mice bearing human SKOV-3 ovarian carcinoma xenografts and evaluated the plasma, tissue, and tumor disposition of each agent alone and in combination. The following treatment
George R Simon et al.
Molecular cancer therapeutics, 5(8), 2130-2137 (2006-08-25)
Resistance to topoisomerase (topo) I inhibitors has been related to down-regulation of nuclear target enzyme, whereas sensitization to topo II inhibitors may result from induction of topo II by topo I inhibitors. Here, we evaluated a sequence-specific administration of a
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持